Literature DB >> 20410817

Purified vs. nonpurified venom immunotherapy.

M Beatrice Bilò1, Leonardo Antonicelli, Floriano Bonifazi.   

Abstract

PURPOSE OF REVIEW: Although highly effective, venom immunotherapy (VIT) may be responsible for local and systemic allergic reactions. There is a good theoretical basis for believing that purified aqueous and purified aluminium hydroxide adsorbed (so-called depot) extracts, commercially available in Europe, have the potential to reduce the incidence of VIT's side effects. The aim of this article is to review the literature on safety and effectiveness of purified preparations as well as compare them with nonpurified extracts. RECENT
FINDINGS: Old and new noncomparative studies reveal good tolerance of purified aqueous and purified depot extracts. In comparative trials purified extracts appear to be better tolerated than nonpurified extracts, whereas depot extracts seem to be safer than the corresponding purified aqueous preparation, especially in the prevention of severe large local reactions. The efficacy of purified aqueous and depot extracts is supported by studies using both sting challenge and in-field stings and is comparable to that of nonpurified preparations.
SUMMARY: The theoretical basis of the safer profile of purified extracts is supported by a number of clinical studies, making the use of purified depot preparations preferable for conventional treatment also by specialists with less experience in managing VIT. In specialized centres purified aqueous extracts may be preferred for faster build-up protocols. However, further prospective controlled studies are needed in order to evaluate the ability of purified extracts to reduce the frequency of severe systemic reactions over the corresponding nonpurified preparation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20410817     DOI: 10.1097/ACI.0b013e328339f2d1

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  8 in total

Review 1.  Venom immunotherapy: an updated review.

Authors:  Darío Antolín-Amérigo; Carmen Moreno Aguilar; Arantza Vega; Melchor Alvarez-Mon
Journal:  Curr Allergy Asthma Rep       Date:  2014-07       Impact factor: 4.806

2.  Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement.

Authors:  Marek L Kowalski; Ignacio Ansotegui; Werner Aberer; Mona Al-Ahmad; Mubeccel Akdis; Barbara K Ballmer-Weber; Kirsten Beyer; Miguel Blanca; Simon Brown; Chaweewan Bunnag; Arnaldo Capriles Hulett; Mariana Castells; Hiok Hee Chng; Frederic De Blay; Motohiro Ebisawa; Stanley Fineman; David B K Golden; Tari Haahtela; Michael Kaliner; Connie Katelaris; Bee Wah Lee; Joanna Makowska; Ulrich Muller; Joaquim Mullol; John Oppenheimer; Hae-Sim Park; James Parkerson; Giovanni Passalacqua; Ruby Pawankar; Harald Renz; Franziska Rueff; Mario Sanchez-Borges; Joaquin Sastre; Glenis Scadding; Scott Sicherer; Pongsakorn Tantilipikorn; James Tracy; Vera van Kempen; Barbara Bohle; G Walter Canonica; Luis Caraballo; Maximiliano Gomez; Komei Ito; Erika Jensen-Jarolim; Mark Larche; Giovanni Melioli; Lars K Poulsen; Rudolf Valenta; Torsten Zuberbier
Journal:  World Allergy Organ J       Date:  2016-10-12       Impact factor: 4.084

3.  Honeybee venom immunotherapy: a comparative study using purified and nonpurified aqueous extracts in patients with normal Basal serum tryptase concentrations.

Authors:  M Beatrice Bilò; Barbara Cinti; M Feliciana Brianzoni; M Chiara Braschi; Martina Bonifazi; Leonardo Antonicelli
Journal:  J Allergy (Cairo)       Date:  2012-01-12

4.  Component-resolved evaluation of the content of major allergens in therapeutic extracts for specific immunotherapy of honeybee venom allergy.

Authors:  Simon Blank; Stefanie Etzold; Ulf Darsow; Maximilian Schiener; Bernadette Eberlein; Dennis Russkamp; Sara Wolf; Anke Graessel; Tilo Biedermann; Markus Ollert; Carsten B Schmidt-Weber
Journal:  Hum Vaccin Immunother       Date:  2017-05-11       Impact factor: 3.452

5.  Efficacy and safety of honeybee and wasp tyrosine-adsorbed venom immunotherapy.

Authors:  Maurizio Severino; Livio Simioni; Patrizia Bonadonna; Renato Cantone; Gabriele Cortellini; Stefano Crescioli; Anna D'Angelo; Luigi La Rosa; Donatella Macchia; Irene Martignago; Alessandro Massolo; Federico Reccardini; Diego Bagnasco; Giovanni Passalacqua
Journal:  World Allergy Organ J       Date:  2019-11-19       Impact factor: 4.084

6.  Safety and tolerability of venom immunotherapy: Evaluation of 581 rush- and ultra-rush induction protocols (safety of rush and ultra-rush venom immunotherapy).

Authors:  Richard Stock; Tatjana Fischer; Katharina Aẞmus; Nadja Zoeller; Hanns Ackermann; Roland Kaufmann; Markus Meissner; Eva Valesky
Journal:  World Allergy Organ J       Date:  2020-12-15       Impact factor: 4.084

7.  Adverse reactions in venom immunotherapy protocols: conventional versus ultra-rush.

Authors:  Ali Selcuk; Abdullah Baysan; Sait Yesillik; Fevzi Demirel; Ozgur Kartal; Mustafa Gulec; Ugur Musabak; Osman Sener
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

Review 8.  Wasp Venom Biochemical Components and Their Potential in Biological Applications and Nanotechnological Interventions.

Authors:  Aida Abd El-Wahed; Nermeen Yosri; Hanem H Sakr; Ming Du; Ahmed F M Algethami; Chao Zhao; Ahmed H Abdelazeem; Haroon Elrasheid Tahir; Saad H D Masry; Mohamed M Abdel-Daim; Syed Ghulam Musharraf; Islam El-Garawani; Guoyin Kai; Yahya Al Naggar; Shaden A M Khalifa; Hesham R El-Seedi
Journal:  Toxins (Basel)       Date:  2021-03-12       Impact factor: 4.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.